Ticagrelor Tablet
Product Images NDC 43598-629

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 43598-629). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1_90mg (Carton1 90mg)

Ticagrelor Tablets 90 mg oral tablets packaging label from Dr. Reddy's Laboratories Inc. The label states each tablet contains 90 mg ticagrelor and includes 10 unit-dose tablets. It advises keeping the medication out of reach of children and storing it at controlled room temperature. The label also instructs pharmacists to dispense the Medication Guide to patients.*

FDA Label Image

Carton2_90mg (Carton2 90mg)

Ticagrelor Tablets 90 mg oral tablet packaging label from Dr. Reddy's Laboratories Inc. The label includes directions for usual adult dosage, storage instructions, and a pharmacist note to dispense the Medication Guide. The package contains 100 tablets in unit-dose format (10 blister cards, each with 10 tablets). The label displays the NDC number 43598-480-78 and includes warnings to keep out of reach of children.*

FDA Label Image

Container90mg (Container90mg)

Label for Ticagrelor Tablets 90 mg by Dr. Reddys Laboratories Inc. The label indicates a package containing 60 tablets. It includes directions for pharmacists to dispense the medication guide to patients, warnings for storage and usage, and features a barcode and QR code for accessing the medication guide online. The label dimensions are 115 mm by 40 mm.*

FDA Label Image

Figure1 (Figure1)

A cumulative percentage line graph comparing two drugs, Ticagrelor 90 mg and Clopidogrel, over 360 days from the first study drug dose. The vertical axis shows cumulative percentage, and the horizontal axis shows days. The graph includes risk data and patient events for each drug at various time points.*

FDA Label Image

Figure10 (Figure10)

A Kaplan-Meier cumulative incidence curve showing percentage of patients with events over 360 days comparing Ticagrelor 90 mg with Clopidogrel. The chart includes patient numbers at risk at various time points and statistical data including hazard ratio and p-value.*

FDA Label Image

Figure11 (Figure11)

A forest plot comparing the overall treatment effect and subgroup analysis of Ticagrelor versus Clopidogrel. It includes hazard ratios (HR) with 95% confidence intervals for various characteristics such as geographic region, aspirin dose, treatment approach, medical treatment, diabetes history, prior stroke, age groups, sex, and race. The plot visually presents the relative risk favoring Ticagrelor or Clopidogrel based on these subgroups.*

FDA Label Image

Figure12 (Figure12)

A data table showing comparative event counts and hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel across different aspirin dose (ASA Dose) categories and regions (US and Non-US). The table includes sample sizes (N) and event counts for each group, with corresponding HR values and a forest plot illustrating the comparative risk estimates.*

FDA Label Image

Figure13 (Figure13)

A line graph showing cumulative percentage of patients with events over days from randomization for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The x-axis represents days from randomization (0 to 1320), and the y-axis shows cumulative percentage (0 to 11%). The graph includes risk percentages, hazard ratios, and p-values for the groups, with a legend distinguishing the three groups by line style.*

FDA Label Image

Figure14 (Figure14)

A forest plot chart illustrating the hazard ratios (HR) and 95% confidence intervals (CI) for various subgroup characteristics comparing Ticagrelor versus placebo treatment effects. It includes categories such as age group, sex, race, weight group, BMI, geographic region, medical history, diabetes status, coronary artery disease presence, creatinine clearance, type of stent, smoking status, and duration of prior receptor blocker treatment, showing relative risk comparisons between Ticagrelor and placebo.*

FDA Label Image

Figure15 (Figure15)

A line chart depicting cumulative percentage over months from randomization, comparing Ticagrelor and placebo groups. The x-axis represents months from 0 to 54, and the y-axis shows cumulative percentage from 0 to approximately 14%. Two lines are plotted: a solid line for Ticagrelor and a dashed line for placebo, with numerical data points and risk numbers listed below the chart.*

FDA Label Image

Figure16 (Figure16)

A forest plot comparing hazard ratios (HR) and 95% confidence intervals (CI) for Ticagrelor versus placebo across various patient subgroups. The plot includes categories such as age, sex, race, body mass index, geographic region, aspirin dose, HbA1c levels, eGFR, history of angina, coronary artery disease, PCI and CABG history, smoking status, and diabetes duration, showing points with confidence intervals to illustrate relative risk and subgroup analyses.*

FDA Label Image

Figure17 (Figure17)

A Kaplan-Meier curve chart showing cumulative percentage over time (days from randomization) comparing Ticagrelor 90 mg twice daily and placebo groups. The graph includes event counts and survival probabilities with time points labeled along the x-axis and cumulative percentage on the y-axis.*

FDA Label Image

Figure18 (Figure18)

A forest plot chart comparing the hazard ratios (HRs) with 95% confidence intervals for various patient characteristics between Ticagrelor and placebo groups. The chart shows subgroups including age, sex, race, weight, BMI, geographic region, diagnosis, diabetes status, hypertension, prior treatments, and smoking status, illustrating relative risk assessment across these categories.*

FDA Label Image

Figure2 (Figure2)

A bar chart illustrating the percentage of patients who had an event following CABG over a series of days. Two groups labeled T and C are compared for days 1 through 8 and beyond, with data values displayed below the x-axis. The y-axis represents the percentage from 0 to 100%. This figure shows relative event rates for each day post-CABG between the two groups.*

FDA Label Image

Figure3 (Figure3)

A cumulative percentage line graph comparing Ticagrelor and placebo over 54 months from randomization. The solid line represents Ticagrelor with a higher cumulative event percentage than the dashed line for placebo, showing data points at regular intervals up to 54 months. The graph includes numbers at risk for both groups along the x-axis.*

FDA Label Image

Figure4 (Figure4)

A cumulative incidence curve comparing Ticagrelor 90 mg twice daily with placebo over 34 days post-randomization. The graph plots cumulative percentage on the Y-axis versus days from randomization on the X-axis, illustrating different event rates between the two groups across time.*

FDA Label Image

Figure5 (Figure5)

A line graph comparing the inhibition of platelet aggregation (IPA%) over an 8-hour period for Ticagrelor 180 mg, Clopidogrel 600 mg, and a placebo. The x-axis represents time in hours, while the y-axis shows IPA percentage. Ticagrelor shows a rapid and higher IPA response compared to Clopidogrel and placebo.*

FDA Label Image

Figure6 (Figure6)

A line chart depicting IPA (%) induced by 20 uM ADP over time (days) with three data series represented by circles, triangles, and squares. An inset graph shows IPA (%) over time (hours) with similar data markers. The y-axis shows IPA percentage from 0 to 100, and the x-axes show time in days and hours respectively.*

FDA Label Image

Figure7 (Figure7)

A chart titled 'Mean effect and 90% CI' showing the effects of intrinsic factors on Ticagrelor pharmacokinetics, with Cmax and AUC values represented by squares and triangles, respectively. The chart compares variables like age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment with recommendations indicating no dose adjustment across all factors.*

FDA Label Image

Figure8 (Figure8)

A pharmacokinetic chart showing the mean effect and 90% confidence interval of various interacting drugs on the concentrations of Ticagrelor and AR-C124910XX. It lists interacting drugs with corresponding recommendations such as dose adjustments or avoidance, including strong/moderate CYP3A4 inhibitors, potent CYP3A4 inducers, and other agents like aspirin and morphine. The x-axis represents change relative to reference, with pharmacokinetic parameters Cmax and AUC indicated by squares and triangles, respectively.*

FDA Label Image

Figure9 (Figure9)

A chart showing the effect and 90% confidence intervals of various interacting drugs when combined with different doses of Ticagrelor. The X-axis represents the change relative to the interacting drug alone, with plotted points indicating mean effects for drugs including Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. Recommendations for dose adjustments or no adjustment are provided on the right side of the chart.*

FDA Label Image

Logo1 (Logo1)

Chemical structure of Ticagrelor, a pharmaceutical compound used in oral tablet form. The diagram depicts the molecule's detailed atomic arrangement and bond connectivity.*

FDA Label Image

Structure1 (Structure1)

Chemical structure of ticagrelor, showing its molecular arrangement including fluorine atoms, hydroxyl groups, and a thioether side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.